Two Distinct Mutations Cause Severe Hemophilia B in Two Unrelated Canine Pedigrees

Summary

The molecular defects causing severe factor IX deficiency were identified in two distinct canine breed-variants. Both defects were associated with an absence of plasma factor IX coagulant activity and antigen. A large deletion mutation was found in 1 breed variant, spanning the entire 5’ region of the factor IX gene extending to exon 6. An approximately 5 kb insertion disrupted exon 8 of the second breed-variant. This insertion was associated with alternative splicing between a donor site 5’ and acceptor site 3’ to the normal exon 8 splice junction, with introduction of a new stop codon. The resultant transcript lacked most of the factor IX catalytic domain and 3’ untranslated region. Molecular analyses of canine hemophilia B define an experimental model for study of inhibitor formation and gene therapy strategies, and provide insight into spontaneous mutation mechanisms in the factor IX gene and on the X chromosome of mammalian species.

¹ Current address: Dr. Kunal Ray, Indian Institute of Chemical Biology, Jadavpur, Calcutta

² Current address: Dr. Weikuan Gu, Molecular Genetics Center, JL Pettis Memorial VAMC and Loma Linda University, Loma Linda, CA, USA

• References

• 1 Kalafatis M, Egan JO, van’t Veer C, Mann KG. Regulation and regulatory role of γ-carboxyglutamic acid containing clotting factors. Crit Rev Eukaryot Gene Expr 1996; 6: 87-101.
• 2 Thompson AR. Molecular Biology of the Hemophilias. In: Progress in Hemostasis and Thrombosis. Coller BS. ed. Philadelphia: WB Saunders; 1991: 175-214.
• 3 Green PM, Montandon AJ, Ljung R, Bentley DR, Nilsson IM, Kling S, Giannelli F. Haemophilia B mutations in a complete Swedish population sample: a test of new strategy for the genetic counseling of diseases with high mutational heterogeneity. Br J Haematol 1991; 78: 390-7.
• 4 Knobloch O, Zoll B, Zerres K, Brackmann HH, Olek K, Ludwig M. Recurrent mutations in the factor IX gene: founder effect or repeat de novo events. Hum Genet 1993; 92: 40-8.
• 5 Giannelli F, Green PM, Sommer SS, Poon MC, Ludwig M, Schwaab R, Reitsma PH, Goossens M, Yoshioka A, Figueiredo MS, Brownlee GG, Haemophilia B. database of point mutations and short additions and deletions-Eighth edition. Nucleic Acids Res 1998; 26: 265-8.
• 6 Green PM, Bentley DR, Mibashan RN, Nilsson IM, Giannelli F. Molecular pathology of haemophilia B. EMBO 1989; 8: 1067-72.
• 7 Gianelli F, Choo KH, Rees DJG, Boyd Y, Rizza CR, Brownlee GG. Gene deletions in patients with haemophilia B and anti-factor IX antibodies. Nature 1983; 303: 181-2.
• 8 Reitsma PH, Mandalaki T, Kasper CK, Bertina RM, Briet E. Two novel point mutations correlate with an altered developmental expression of blood coagulation factor IX (hemophilia B Leiden phenotype). Blood 1989; 73: 743-6.
• 9 Koeberl DD, Bottema CDK, Ketterling RP, Bridge PJ, Lillicrap DP, Sommer SS. Mutations causing hemophilia B: direct estimates of the underlying rates of spontaneous germ-line transitions, transversions, and deletions in a human gene. Am J Hum Genet 1990; 47: 202-17.
• 10 Sommer SS, Ketterling RP. How precisely can data from transgenic mouse mutation-detection systems be extrapolated to humans?: lessons from the human factor IX gene. Mut Res 1994; 307: 517-31.
• 11 Lin HF, Maida N, Smithies O, Straight DL, Stafford DW. A coagulation factor IX deficient mouse model for human hemophilia B. Blood 1997; 90: 3962-6.
• 12 Wang L, Zoppe M, Hackeng TM, Griffen JH, Lee KF, Verma IM. A factor IX deficient mouse model for hemophilia B gene therapy. Proc Natl Acad Sci 1997; 94: 11563.
• 13 Kundu RK, Sangiogi F, Wu LY, Kurachi K, Anderson WF, Maxson R, Gordon EM. Targeted inactivation of the coagulation factor IX gene causes hemophilia B in mice. Blood 1998; 92: 168-74.
• 14 Brooks MB. A review of canine inherited bleeding disorders: biochemical and molecular strategies for disease characterization and carrier detection. J Heredity 1999; 90: 112-8.
• 15 Evans JP, Brinkhous KM, Brayer GD, Reisner HM, High KA. Canine hemophilia B resulting from a point mutation with unusual consequences. Proc Natl Acad Sci 1989; 86: 10095-9.
• 16 Mauser AE, Witlark J, Whitney KM, Lothrop CD. A deletion mutation causes hemophilia B in Lhasa Apso dogs. Blood 1996; 88: 3451-5.
• 17 Brooks MB, Bu W, Ray K. Complete deletion of the factor IX gene and inhibition of factor IX activity in a Labrador retriever with hemophilia B. J Am Vet Med Assoc 1997; 211: 1418-21.
• 18 Triplett DA. Factor VIII or IX Assay. In: Procedures for the Coagulation Laboratory. Triplett DA, Harms CS. eds. Chicago: ASCP; 1981: 38-41.
• 19 Benson RE, Catalfamo JL, Brooks MB, Dodds WJ. A sensitive immunoassay for von Willebrand factor. J Immunoassay 1991; 12: 371-90.
• 20 Kay MA, Rothenburg S, Landen CN, Bellinger Da, Leland F, Toman C, Finegold M, Thompson AR, Read MS, Brinkhous KM, Woo SLC. In vivo gene therapy of hemophilia B: sustained partial correction in factor IX-deficient dogs. Science 1993; 262: 117-9.
• 21 Sugahara Y, Catalfamo JF, Brooks M, Hitomi E, Bajaj SP, Kurachi K. Isolation and characterization of canine factor IX. Thromb Haemost 1996; 75: 450-5.
• 22 Sambrook J, Fritsch EF, Maniatis T. Analysis and Cloning of Eukaroyic Genomic DNA. In: Molecular Cloning, A Laboratory Manual 2^nd ed.. Cold Spring Harbor: Cold Spring Harbor Laboratory Press; 1989: 9.17-19.
• 23 Church GM, Gilbert W. Genomic sequencing. Proc Natl Acad Sci 1984; 81: 1991-5.
• 24 Evans JP, Watzke HH, Ware JL, Stafford DW, High KA. Molecular cloning of cDNA encoding canine factor IX. Blood 1989; 74: 207-12.
• 25 Yoshitake S, Schach G, Foster DC, Davie EW, Kurachi K. Nucleotide sequence of the gene for human factor IX (Antihemophilic Factor B). Biochemistry 1985; 24: 3736-50.
• 26 Chomczynski P, Saachi N. Single-step method for RNA isolation by acidguanidium thiocyanate phenol chloroform extraction. Anal Biochem 1987; 162: 156-9.
• 27 Sharp PA. Speculations on RNA splicing. Cell 1981; 23: 643-6.
• 28 Frazier D, Smith KJ, Cheung WF, Ware J, Lin SW, Thompson AR, Reisner H, Bajaj SP, Stafford DW. Mapping of monoclonal antibodies to human factor IX. Blood 1989; 74: 971-7.
• 29 Chen SH, Scott CR, Edson JR, Kurachi K. An insertion within the factor IX gene: hemophilia B_{El Salvador} . AM J Hum Genet 1988; 42: 581-4.
• 30 Darvasi A, Kerem B. Deletion and insertion mutations in short tandem repeats in the coding regions of human genes. Eur J Hum Genet 1995; 3: 14-20.
• 31 Burton FH, Loeb DD, Voliva CF, Martin SL, Edgell MH, Hutchinson CA. Conservation throughout mammalia and extensive protein-encoding capacity of the highly repeated DNA long interspersed sequence one. J Mol Biol 1986; 187: 291-304.
• 32 Schwahn U, Lenzner S, Dong J, Feil S, Hinzmann B, v Duijnhoven G, Kirschner R, Hemberger M, Bergen A, Rosenberg T, Pinckers A, Fundele R, Rosenthan A, Cremers F, Ropers H, Berger W. Positional cloning of the gene for X-linked retinitis pigmentosa 2. Nat Genet 1998; 19: 327-32.
• 33 Narita N, Nishio H, Kitoh Y, Ishikawa Y, Minami R, Nakamura H, Matsuo M. Insertion of a 5’ truncated L1 element into the 3’ end of exon 44 of the dystrophin gene resulted in skipping of the exon during splicing in a case of Duchenne muscular dystrophy. J Clin Invest 1993; 91: 1862-7.
• 34 Kazazian HH, Wong C, Yossaoufian H. Haemophilia A resulting from de novo insertion of L1 sequences represents a novel mechanism for mutation in man. Nature 1988; 332: 164-6.